Nomura is also an editor for Cell Chemical Biology and Current Protocols in Chemical Biology. He is also the director of the Novartis-Berkeley Center for Proteomics and Chemistry Technologies. He is also an adjunct professor in the Department of Pharmaceutical Chemistry at UCSF. We can also share audience insights on job titles, seniority and geography of attendees, so you know this is the right event to match your business needs.ĭan Nomura is a professor in the Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology at the University of California, Berkeley.
Increased Content – we can run more sessions at one time without the constraints of venue capacities, meaning we can provide you with more valuable content in one go.Save Time & Money – tune into an event from the comfort of your own home, no need to travel overseas, spend time away from loved ones and spend your companies money! This makes lead gen and knowledge sharing much more cost efficient.Get More Involved – virtual events offer many more interactive opportunities than live events participate in live polls, live Q&A and live panel discussions – helping you build you personal brand and your business connections.
We will bring together leading industry players within large pharma and biotech,along with expert academics in the oncology drug discovery space – providing an open forum to facilitate the sharing of in vitro and in vivo data, as well as build a deeper understanding of transcriptional machinery to make the ‘undruggable’ druggable.Įxpect to hear strategies to overcome the structural biology, pharmacology, and chemistry obstacles in the design and development of TF-based therapeutics by hearing real success stories in the targeting of transcription factors for therapeutic benefit.ĭevelop further insight into targeting MYC, STAT, and other transcription factors with a role in disease. The inaugural Transcription Factor Drug Development Congress is the first of its kind anywhere in the world! With multiple strategies having entered the clinic from PPI inhibitors, modulators of TF expression, and the first PROTAC-based degraders, it could only be a matter of time before the first therapy enters the market. With an increasing number of projects entering the pipeline both clinically and pre-clinically aimed at targeting transcription factors that were previously thought to be “undruggable”, the industry is ready to develop further insight into the commercialization of TF-based therapeutics within cancer and other disease settings.
0 kommentar(er)
